On May 28, 2019 Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, reported the Company and its subsidiaries will participate in the 2019 BIO International Convention June 3-6th in Philadelphia (Press release, Intrexon, MAY 28, 2019, View Source [SID1234536600]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Pieter Rottiers, PhD, Chief Executive Officer of ActoBio Therapeutics, a wholly-owned subsidiary of Intrexon and innovative clinical-stage biotechnology company developing a new class of microbe-based therapeutic agents, will be giving a company presentation on Monday June 3rd from 2:15-2:30 pm ET.
Randal J. Kirk, Chairman and Chief Executive Officer of Intrexon, will present in the session "It Starts with One Health: A Guide to Translational Science from Research to Investment" on Monday June 3rd from 2:30-4:00 pm ET, highlighting program areas in both Intrexon Health and Intrexon Bioengineering.
Helen Sabzevari, PhD, President of Precigen, Inc., a wholly-owned subsidiary of Intrexon and a clinical stage biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, will participate in the panel "Immuno-Oncology: Taking Immunotherapies to the Next Level" on June 6th from 10:30 am-12:00 pm ET.
The BIO International Convention in Philadelphia celebrates the globally important innovations in biotech that start with one: one meeting, one theory, one trial, one breakthrough. Attendees will take advantage of unparalleled business partnering, gain insights in hundreds of education sessions, and network with 16,000+ of biotech’s most influential. Learn more at convention.bio.org.
The companies’ presentations will not be webcast.